The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life

By sjmartinez • March 23, 2024

Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncol Pract. 2024 Mar 22:OP2300539. doi: 10.1200/OP.23.00539. Epub ahead of print. PMID: 38518184.

Tags: Hematology/Oncology, Publications

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]